These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 18419422

  • 1. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN.
    Clin Infect Dis; 2008 Jun 01; 46(11):1702-9. PubMed ID: 18419422
    [Abstract] [Full Text] [Related]

  • 2. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.
    Clin Infect Dis; 2009 Jan 15; 48(2):e16-22. PubMed ID: 19093811
    [Abstract] [Full Text] [Related]

  • 3. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 15; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 4. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda JA.
    Am J Trop Med Hyg; 2004 Mar 15; 70(3):298-301. PubMed ID: 15031520
    [Abstract] [Full Text] [Related]

  • 5. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
    Reus S, Sánchez R, Portilla J, Boix V, Priego M, Merino E, Román F.
    Enferm Infecc Microbiol Clin; 1999 Dec 15; 17(10):515-20. PubMed ID: 10650648
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Oct 15; 60(4):837-42. PubMed ID: 17684055
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 11. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.
    AIDS; 2007 Jan 30; 21(3):351-9. PubMed ID: 17255742
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E.
    Parassitologia; 2004 Jun 30; 46(1-2):89-93. PubMed ID: 15305694
    [Abstract] [Full Text] [Related]

  • 14. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
    Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, Hailu A.
    Trop Med Int Health; 2010 Jul 30; 15(7):848-55. PubMed ID: 20487426
    [Abstract] [Full Text] [Related]

  • 15. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.
    AIDS; 2007 Nov 30; 21(18):2483-91. PubMed ID: 18025885
    [Abstract] [Full Text] [Related]

  • 16. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Aug 01; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 18. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
    Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonnière X, Viget N, Ajana F, Goffard A, Barin F, Mouton Y, Yazdanpanah Y.
    Antivir Ther; 2005 Aug 01; 10(2):247-54. PubMed ID: 15865219
    [Abstract] [Full Text] [Related]

  • 19. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.
    Pediatrics; 2005 Apr 01; 115(4):e488-94. PubMed ID: 15772172
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.